Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Passive immunization and its rebirth in the era of the COVID-19 pandemic.

Tytuł :
Passive immunization and its rebirth in the era of the COVID-19 pandemic.
Autorzy :
Pavia CS; Department of Biomedical Sciences, NYIT College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, NY; Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA. Electronic address: .
Wormser GP; Division of Infectious Diseases, New York Medical College, Valhalla, NY, USA.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2021 Jan 02, pp. 106275. Date of Electronic Publication: 2021 Jan 02.
Publication Model :
Ahead of Print
Typ publikacji :
Journal Article; Review
Język :
English
Imprint Name(s) :
Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
References :
Infect Dis Ther. 2020 Dec;9(4):913-926. (PMID: 32951151)
J Clin Invest. 2020 Jun 1;130(6):2757-2765. (PMID: 32254064)
Am J Pathol. 2021 Jan;191(1):90-107. (PMID: 33157066)
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759. (PMID: 32663409)
BMJ. 2020 Jul 3;370:m2648. (PMID: 32620554)
Clin Microbiol Rev. 2000 Oct;13(4):602-14. (PMID: 11023960)
Can J Public Health. 1973 Jul-Aug;64(4):317-36. (PMID: 4581249)
Infect Dis Ther. 2020 Sep;9(3):525-536. (PMID: 32651941)
Prim Care. 2011 Dec;38(4):681-91, viii. (PMID: 22094139)
J Clin Microbiol. 1976 Jul;4(1):61-6. (PMID: 182716)
Clin Infect Dis. 2011 Feb 15;52(4):447-56. (PMID: 21248066)
J Infect Dis. 2015 Jan 1;211(1):80-90. (PMID: 25030060)
Clin Infect Dis. 1997 Jul;25 Suppl 1:S25-30. (PMID: 9233660)
JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428)
BMJ. 2020 Mar 26;368:m1256. (PMID: 32217555)
Clin Trials. 2016 Feb;13(1):13-21. (PMID: 26768570)
Trials. 2020 Jun 8;21(1):499. (PMID: 32513308)
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. (PMID: 32253318)
Diagn Microbiol Infect Dis. 2020 Dec;98(4):115148. (PMID: 32920452)
BMJ. 2020 Oct 22;371:m3939. (PMID: 33093056)
JAMA. 2020 Aug 4;324(5):460-470. (PMID: 32492084)
Contributed Indexing :
Keywords: COVID-19; Convalescent plasma; Immune globulin; Monoclonal antibodies; Passive immunization; SARS-CoV-2
Entry Date(s) :
Date Created: 20210105 Latest Revision: 20210129
Update Code :
20210210
PubMed Central ID :
PMC7834679
DOI :
10.1016/j.ijantimicag.2020.106275
PMID :
33400975
Czasopismo naukowe
The COVID-19 pandemic, caused by SARS-CoV-2, has led to a rapid search for therapeutic and preventive measures because of the potentially severe course of infection. The antiviral drug, remdesivir, and the anti-inflammatory agent, dexamethasone, have shown beneficial effects. As the current COVID-19 vaccines are not yet fully available to everyone, or they may not be readily and universally accepted, various treatment options are being evaluated and will still be needed under these conditions. One of these treatment options, passive immunization, has shown promise in some studies. Further research is needed to determine the utility of immunotherapy with convalescent plasma or artificially produced monoclonal antibodies for the treatment of symptomatic patients, and potentially for use as post-exposure prophylaxis, at least until more effective drugs are available or safe and effective vaccines are distributed and administered to everyone.
(Copyright © 2021. Published by Elsevier Ltd.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies